About Alvine Pharma
Alvine Pharma is a Healthcare company based in San Carlos (United States) founded in 2005, and was acquired by Immunogenx in March 2016. Developing therapeutics for autoimmune and inflammatory diseases. Alvine Pharma has raised $128.51 million across 6 funding rounds from investors including AbbVie, Flagship Pioneering and Immunogenx. Alvine Pharma offers products and services including LLC Formation Service, Registered Agent Service, and Trademark Service. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.
Company details
Alvine is developing biologics to target autoimmuneinflammatory diseases. The companys initial focus targets celiac disease. Celiac disease is a gluten-induced autoimmune disease for which no drug therapy is presently available. Alvines lead product candidate, ALV003, is a combination protease engineered to digest gluten and is currently in phase 2b.
- Headquarters San Carlos, United States
- Stage Acquired
- SectorsHealthcare
- Website alvinepharma.com
- Social LinkedIn
- Acquired by Immunogenx (Mar 2016)
- Total Equity Funding$128.51M (USD)
in 6 rounds
- Latest Funding Round$70M (USD), Series B
May 2013
- InvestorsAbbVie
& 8 more
- Acquired byImmunogenx
(Mar 2016)
Products & Services of Alvine Pharma
Alvine Pharma offers a comprehensive portfolio of products and services, including LLC Formation Service, Registered Agent Service, and Trademark Service.
Assists in forming limited liability companies for business owners.
Handles legal documents and ensures business compliance requirements.
Provides guidance on protecting business brands and trademarks.
Funding Insights of Alvine Pharma
Alvine Pharma has successfully raised a total of $128.51M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $70 million completed in May 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $128.51M
- Total Rounds 6
- Last Round Series B — $70M
- First Round $26.01M
(May 2008)
- Investors Count 8
All 6 funding rounds of Alvine Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2013 | $70M | Series B | – | AbbVie | – |
| Jan 2013 | $6.01M | Series A | – | – | – |
| Oct 2011 | $6.01M | Debt – Convertible | – | – | – |
| Mar 2011 | $26.5M | Series A | – | Panorama Capital | |
| May 2010 | Series A | – | – | ||
| May 2008 | $26.01M | Series A | – | – |
9 investors in total: 9 institutional.
Investors in Alvine Pharma
Alvine Pharma has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, Flagship Pioneering and Immunogenx.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early & later stage venture capital firm investing in the US | panoramacapital.com | Campbell, United States | ||
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Investments are made in US life sciences and healthtech firms. | prospectventures.com | Palo Alto, United States | ||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Venture capital firm focused on information technology, life sciences, and clean technology sectors | cargillventures.com | San Mateo, United States | ||
Global macro strategies are pursued by Black River hedge fund. | black-river.ch | Zug, Switzerland | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | abbvie.com | Chicago, United States | |
Solutions for treatment and management of celiac disease | 2013 | immunogenx.com | Durham, United States |
Investor details for Alvine Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Alvine Pharma
4 dated milestones of Alvine Pharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Alvine Pharma is founded.
- Funding First funding round of $26.0M.
- Funding Latest funding round, Series B, of $70.0M.
- Exit Acquired by Immunogenx.
Competitors of Alvine Pharma
Alvine Pharma has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. |
Detailed competitors of Alvine Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Alvine Pharma (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Alvine Pharma
Alvine Pharma was founded in 2005 and raised its 1st funding round 3 years after it was founded.
Alvine Pharma is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Alvine Pharma is a funded company, having raised a total of $128.51M across 6 funding rounds to date. The company's 1st funding round was a Series A of $26.01M, raised on May 2008.
Alvine is developing biologics to target autoimmuneinflammatory diseases. The companys initial focus targets celiac disease. Celiac disease is a gluten-induced autoimmune disease for which no drug therapy is presently available. Alvines lead product candidate, ALV003, is a combination protease engineered to digest gluten and is currently in phase 2b.
Alvine Pharma's top competitors include ADMA Biologics, Kymeratx and Biogen.
Alvine Pharma offers LLC Formation Service, Registered Agent Service, and Trademark Service.
Alvine Pharma has 9 investors. Key investors include AbbVie, Flagship Pioneering, Immunogenx, Panorama Capital, and InterWest.
Yes. Alvine Pharma was acquired by Immunogenx in March 2016.